Attributes | Values |
---|
rdf:type
| |
description
| - clinical trial (en)
- ensayu clínicu (ast)
- klinisch onderzoek (nl)
- клінічне випробування (uk)
|
rdfs:label
| - Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (en)
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (nl)
|
skos:prefLabel
| - Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (en)
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (nl)
|
name
| - Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (en)
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia (nl)
|
title
| |
title
| - Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study (en)
|
end time
| |
end time
| |
instance of
| |
instance of
| |
start time
| |
start time
| |
country
| |
country
| |
research site
| |
research site
| |
research intervention
| |
research intervention
| |
medical condition
| |
medical condition
| |
number of participants
| |
number of participants
| |
maximum age
| |
maximum age
| |
study type
| |
study type
| |
ClinicalTrials.gov ID
| |
ClinicalTrials.gov ID
| |
clinical trial phase
| |
clinical trial phase
| |
is about
of | |